m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00942)
Name
Dicloxacillin
Synonyms
(2S,5R,6R)-6-({[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-({[3-(2,6-dichlorophenyl)-5-methylisoxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 3-(2,6-Dichlorophenyl)-5-methyl-4-isoxazolylpenicillin; 6-(3-(2,6-Dichlorophenyl)-5-methyl-4-isoxazolecarboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 6-(3-(2,6-Dichlorophenyl)-5-methyl-4-isoxazolecarboxamido)penicillanic acid; 6beta-{[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]carboxamido}-2,2-dimethylpenam-3alpha-carboxylic acid; BRL 1702; Dichloroxacillin; Diclocil (TN); Diclossacillina; Diclossacillina [DCIT]; Dicloxaciclin; Dicloxacilin; Dicloxacilina; Dicloxacilina [INN-Spanish]; Dicloxacillin (USAN/INN); Dicloxacillin [USAN:INN:BAN]; Dicloxacillin sodium; Dicloxacillin, Monosodium Salt, Mono-Hydrate; Dicloxacilline; Dicloxacilline [INN-French]; Dicloxacillinum; Dicloxacillinum [INN-Latin]; Dicloxacycline; Dycill; Dynapen; Maclicine; Methyldichlorophenylisoxazolylpenicillin; Pathocil; R-13423
    Click to Show/Hide
Status
Approved
Structure
Formula
C19H17Cl2N3O5S
InChI
1S/C19H17Cl2N3O5S/c1-7-10(12(23-29-7)11-8(20)5-4-6-9(11)21)15(25)22-13-16(26)24-14(18(27)28)19(2,3)30-17(13)24/h4-6,13-14,17H,1-3H3,(H,22,25)(H,27,28)/t13-,14+,17-/m1/s1
InChIKey
YFAGHNZHGGCZAX-JKIFEVAISA-N
PubChem CID
18381
VARIDT Drug ID
DR00455
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
P-glycoprotein 1 (ABCB1)
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary P-glycoprotein 1 (ABCB1) is a therapeutic target for Dicloxacillin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Dicloxacillin through regulating the expression of P-glycoprotein 1 (ABCB1). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary P-glycoprotein 1 (ABCB1) is a therapeutic target for Dicloxacillin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dicloxacillin through regulating the expression of P-glycoprotein 1 (ABCB1). [2], [3]
References
Ref 1 Binding of RNA m6A by IGF2BP3 triggers chemoresistance of HCT8 cells via upregulation of ABCB1. Am J Cancer Res. 2021 Apr 15;11(4):1428-1445. eCollection 2021.
Ref 2 Can the enhanced renal clearance of antibiotics in cystic fibrosis patients be explained by P-glycoprotein transport?. Pharm Res. 2002 Apr;19(4):457-62. doi: 10.1023/a:1015191511817.
Ref 3 METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner. Exp Mol Med. 2021 Jan;53(1):91-102. doi: 10.1038/s12276-020-00510-w. Epub 2021 Jan 8.